ZOVOO
10.12.2021 09:28:14 CET | Business Wire | Press release
ZOVOO , founded in 2019 and emerging as a dark horse in the electronic cigarette industry, recently launched its latest product Dragbar and achieved a sales milestone of over 1,000,000 pieces in the global market in less than one month, fully demonstrating the extraordinary strength of ZOVOO .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005123/en/
User-oriented and differentiated to meet market demand
According to ZOVOO' s global sales analysis, ZOVOO had an impressive performance in Southeast Asia, North America and Europe, which is attributable to not only Dragbar' s excellent capability, but also the ZOVOO team's in-depth and detailed market analysis of different regions.
Dragbar' s innovation and research team employed polymer fibers and ergonomic lip sensation design to address the consumers' most-concerned issues such as oil leakage and dry hit, while also ensuring the taste and recovery of the product. Using the most popular double injection molding process and the collision of extremely vibrant colors, the high-quality product is aesthetically attractive and tasteful, and soon gained the recognition of the consumers.
Product preference varies in different markets, so the team made in-depth investigations on product appearances and sizes and provided different series of Dragbar to cater to users in different regions, eventually achieving sales performance that was in line with the target of the ZOVOO team.
Creating amazing products with extreme craftsmanship
The ZOVOO design team, with its decade-long history, consists of senior creative elites, concept artists, visual designers and technical engineers. As ZOVOO 's first product for the overseas market, Dragbar cost the design team a whole year to finish. Even after thousands of adjustments, tests, and appearance improvements, the team did not start mass production until it was 100% confident with the final product.
In addition, since the founding of ZOVOO , the team has been focused on technology, constantly making breakthroughs and pursuing new patents and new technologies. During the long process ranging from research and development to design, production, and testing before the launch of each product, the innovation and research team is particular about every detail of the product, so as to bring comfortable and safe experience to the consumers.
Dragbar' s sales volume of 1,000,000 pieces achieved in a short period of time fully demonstrated the ZOVOO team's accurate insight into the users' needs, its excellent research and development capabilities, as well as its forward-looking product design strength. With the excellent performance of Dragbar, ZOVOO has successfully entered markets in more than 50 countries and regions in North America, Europe and Southeast Asia. In the future, the ZOVOO team will continue to develop new products in line with market trends to meet the users' new needs.
About ZOVOO
ZOVOO has established strategic partnerships with ICCPP manufacturers on a basis of mutual trust. ZOVOO enables its sustainable supply chain management by supporting safety standards, social values and environment-friendliness. With the motto of "Creating is Endless", ZOVOO is committed to adding inspirations to the colorful life of people with technology, and seeking partners globally to better serve the consumers.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical. The product is only intended for adult smokers of legal purchase age.
ZOVOO Official Website: https://www.izovoo.com/
IG: https://www.instagram.com/zovoo_tech/
Facebook: https://www.facebook.com/zovootechofficial
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005123/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom